Copyright © Inderes 2011 - present. All rights reserved.
  • Uusimmat
  • Pörssi
    • Aamukatsaus
    • Osakevertailu
    • Pörssikalenteri
    • Osinkokalenteri
    • Analyysi
    • Artikkelit
    • Sisäpiirin kaupat
  • inderesTV
  • Mallisalkku
  • Foorumi
  • Premium
  • Femme
  • Opi
    • Sijoituskoulu
    • Q&A
    • Analyysikoulu
  • Meistä
    • Seurantayhtiöt
    • Tiimi
Kolmannen osapuolen analyysi

Nolato: No drama, just solid delivery - ABG

Nolato

Tämä on kolmannen osapuolen analyysi, eikä välttämättä vastaa Inderesin näkemystä tai arvoja

Lataa raportti (PDF)
* More margin gains, 12% target now looking conservative* Adj. EBITA raised by 1-2% for '25e-'27e, mainly from Engineered* Trading at 14.5x '26e EV/EBITA vs. five-year average 15.3xMore margin gains, 12% target now looking conservativeNolato reported a solid set of numbers, with adj. EBITA 2% above Modular Finance IR consensus. The beat was driven by Engineered Solutions, while Medical Solutions came in below expectations. This marked the fourth consecutive quarter of margin expansion, and at an 11.7% adj. EBITA margin, Nolato is now closing in on its 12% target that was introduced as recently as March 2025. We argue that the target, which seemed ambitious a couple of quarters ago, is now starting to look conservative, as we see several avenues for further improvement. These include: 1) the ramp-up of volumes from the new Hungary site starting Q2'26e, which management has said will be margin-accretive to the Medical segment, 2) a recovery in the high-margin materials sub-segment driving positive mix effects, and 3) improvements in the still-underperforming US Medical business.Adj. EBITA raised by 1-2%, driven by EngineeredEngineered cleared our Q3 margin estimate by some distance, and we do not think the underlying drivers are temporary, so we raise the segment's EBITA estimates by 5-7%. Meanwhile, our 1% EBITA cuts in Medical are explained by updated FX assumptions, while our revisions amount to +1-2% on EBITA for '25e-'27e at the group level.14.5x '26e EV/EBITA, slightly below 5Y average 15.3xOn our estimates, the share is now trading at 14.5x '26e EV/EBITA, slightly below its five-year average of 15.3x, offering '26e-'27e lease adj. FCF yields of 5% per year. We also highlight that the higher-quality Medical segment has gone from 34% of EBITA to 59% during the past five years.
Sosiaalinen media
  • Inderes Foorumi
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Yhteystiedot
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • Meistä
  • Tiimi
  • Avoimet työpaikat
  • Inderes sijoituskohteena
  • Palvelut pörssiyhtiöille
Sivusto
  • UKK
  • Käyttöehdot
  • Tietosuojaseloste
  • Vastuuvapauslauseke
Inderesin vastuuvapauslauseke löytyy täältä. Kunkin Inderesin aktiivisessa seurannassa olevan osakkeen tarkemmat tiedot löytyvät kunkin osakkeen omilta yhtiösivuilta Inderes-sivustolla. © Inderes Oyj. Kaikki oikeudet pidätetään.